Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This study highlights the high recurrence of gestational diabetes mellitus (GDM) and its strong association with future type 2 diabetes, particularly among Asian women, underscoring the need for ethnicity-specific prevention and screening s
Baricitinib treatment in recent-onset type 1 diabetes preserves β-cell function during therapy. However, this effect diminishes within a year after stopping treatment, highlighting the need for sustained immunotherapy for lasting benefit.
Mazdutide, a once-weekly glucagon and GLP-1 receptor dual agonist, delivers clinically meaningful weight reduction in adults with obesity or overweight, with higher doses yielding superior outcomes and manageable safety profiles.
The TARTAN-HF trial demonstrated that targeted natriuretic peptide screening in high-risk diabetic patients uncovers a high prevalence of undiagnosed heart failure, mainly HFpEF, enabling earlier treatment initiation and improved clinical c
In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possib
In type 2 diabetes patients with coronary artery disease, suPAR levels remain unchanged despite treatment and independently predict adverse cardiovascular events beyond hs-CRP, highlighting suPAR’s potential in identifying treatment-r
Diabetes significantly increases inpatient admissions and ED visits across all ages, driven increasingly by nontraditional complications. Age-specific risks reveal shifting patterns in healthcare utilization that call for tailored clinical
A nationwide prospective study identifies early fatigue and poor mental health as key predictors of long-term fatigue in differentiated thyroid cancer patients, while thyrotropin suppression shows no association with fatigue.
The DIADEMA trial demonstrates dulaglutide’s superiority over insulin in improving glycaemic variability, pancreatic function, and iron overload, without safety concerns, in adolescents with thalassaemia-induced diabetes.
A comprehensive longitudinal study reveals that menopausal transition does not significantly alter thyroid function beyond normal aging effects in healthy women, clarifying the interplay between menopause and thyroid health.
Circulating miR-1-3p levels rise before clinical signs of adrenarche and regulate adrenal steroid hormone production through protein kinase C signaling pathways.
This study reveals that weight gain exceeding 5% in MASLD patients increases liver-related event risks and liver stiffness, whereas weight loss improves liver stiffness and may reduce adverse outcomes, especially with obesity reversal.
Elevated glucocorticoids, androgens, and progesterone metabolites, combined with high BMI and stress, accelerate the onset of puberty in girls, particularly breast development (thelarche).
Incorporating a type 1 diabetes genetic risk score into MODY genetic testing helps identify misdiagnosed T1D cases, particularly in children, optimizing diagnostic accuracy and reducing unnecessary testing.
A multi-centre phase 2 study demonstrates that belatacept combined with sirolimus achieves superior islet transplant outcomes with better renal preservation compared to conventional tacrolimus-based therapy in type 1 diabetes patients.
Switching from daily somatropin to once-weekly somapacitan in adults with growth hormone deficiency maintains lean mass, improves functional outcomes, but may increase adiposity indices, highlighting a trade-off in metabolic effects during
This review synthesizes evidence on daily and weekly patterns of glycemic control in real-world CGM data, highlighting small but consistent temporal variations that inform personalized diabetes care.
This phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.
Early initiation of insulin within two hours for moderate hyperglycemia in ICU patients significantly lowers 30-day mortality compared to delayed or no insulin therapy. This target trial emulation highlights the potential clinical benefit o
This study reveals a significant association between GLP-1 receptor agonist therapy and increased risk of smell and taste disturbances in type 2 diabetes patients, highlighting the need for awareness and monitoring.
Open language-specific specialty feeds and department pages.